AVANT: GLAXO PAID ROYALTIES AT LOW RATE

Vaccine developer Avant Immunotherapeutics Inc. said that GlaxoSmithKline PLC has paid royalties on its sales of Rotarix rotavirus vaccine in Australia and certain European countries at the lower of two rates established under the companies' 1997 license agreement.
Boston Globe